Insight Molecular Diagnostics (IMDX) EPS (Weighted Average and Diluted): 2022-2025
Historic EPS (Weighted Average and Diluted) for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Sep 2025 value amounting to -$0.34.
- Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) rose 65.31% to -$0.34 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.47, marking a year-over-year increase of 24.25%. This contributed to the annual value of -$4.67 for FY2024, which is 1121.12% down from last year.
- Latest data reveals that Insight Molecular Diagnostics reported EPS (Weighted Average and Diluted) of -$0.34 as of Q3 2025, which was down 13.33% from -$0.30 recorded in Q2 2025.
- Over the past 5 years, Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) peaked at $0.82 during Q1 2023, and registered a low of -$8.16 during Q4 2022.
- In the last 3 years, Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) had a median value of -$0.81 in 2023 and averaged -$0.83.
- Per our database at Business Quant, Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) surged by 835.00% in 2023 and then slumped by 237.80% in 2024.
- Over the past 4 years, Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$8.16 in 2022, then surged by 74.08% to -$2.11 in 2023, then fell by 21.66% to -$2.57 in 2024, then spiked by 65.31% to -$0.34 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.34 for Q3 2025, versus -$0.30 for Q2 2025 and -$0.26 for Q1 2025.